AU2013235275B2 - Methods of treating cancer using aurora kinase inhibitors - Google Patents
Methods of treating cancer using aurora kinase inhibitors Download PDFInfo
- Publication number
- AU2013235275B2 AU2013235275B2 AU2013235275A AU2013235275A AU2013235275B2 AU 2013235275 B2 AU2013235275 B2 AU 2013235275B2 AU 2013235275 A AU2013235275 A AU 2013235275A AU 2013235275 A AU2013235275 A AU 2013235275A AU 2013235275 B2 AU2013235275 B2 AU 2013235275B2
- Authority
- AU
- Australia
- Prior art keywords
- aurora
- kinase
- cancer
- paclitaxel
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613258P | 2012-03-20 | 2012-03-20 | |
| US61/613,258 | 2012-03-20 | ||
| PCT/US2013/032962 WO2013142491A1 (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013235275A1 AU2013235275A1 (en) | 2014-10-23 |
| AU2013235275B2 true AU2013235275B2 (en) | 2017-12-07 |
Family
ID=48048255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013235275A Active AU2013235275B2 (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Country Status (24)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| EP3236948A4 (en) * | 2014-12-23 | 2018-10-03 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| JP6786530B2 (ja) * | 2015-07-02 | 2020-11-18 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー |
| CN114681455A (zh) * | 2018-08-17 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063525A1 (en) * | 2006-11-16 | 2008-05-29 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| CA1138863A (en) | 1979-02-07 | 1983-01-04 | Norman W. Gilman | Benzazepine-derivatives |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| CN1084747C (zh) | 1996-03-08 | 2002-05-15 | 曾尼卡有限公司 | 作为神经活性剂的吡咯并苯并氮杂䓬衍生物 |
| EP0946523A1 (en) | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| CA2305307C (en) | 1997-09-29 | 2004-11-30 | Meiji Seika Kaisha, Ltd. | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| JP2004509115A (ja) | 2000-09-15 | 2004-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| PT1355905E (pt) | 2000-12-21 | 2007-05-31 | Vertex Pharma | Compostos de pirazole úteis como inibidores de proteínaquinase |
| SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (de) | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
| MXPA04001252A (es) | 2001-08-09 | 2004-05-27 | Actelion Pharmaceuticals Ltd | Nuevos heterociclos benzo-fusionados como antagonistas de endotelina. |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| WO2005076987A2 (en) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| BRPI0511139B8 (pt) | 2004-05-14 | 2021-05-25 | Millennium Pharm Inc | compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos |
| AU2005306458B2 (en) | 2004-11-17 | 2011-02-17 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| JP5140600B2 (ja) | 2005-12-23 | 2013-02-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | オーロラキナーゼのアザインドール阻害薬 |
| JP2009523784A (ja) | 2006-01-16 | 2009-06-25 | ジュビラント・オルガノシス・リミテッド | 酸不安定化合物の安定な医薬製剤およびその製造方法 |
| CL2007000667A1 (es) | 2006-03-14 | 2008-03-14 | Ranbaxi Lab Ltd | Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e |
| DE102006012301A1 (de) | 2006-03-15 | 2007-09-20 | Cemag-Anlagenbau-Dessau Gmbh | Herstellung von Zementklinker |
| EP2054413A2 (en) | 2006-08-09 | 2009-05-06 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CA2668267A1 (en) | 2006-10-31 | 2008-05-08 | Achillion Pharmaceuticals, Inc. | Elvucitabine pharmaceutical compositions |
| AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| CA2726836C (en) | 2008-06-26 | 2019-06-18 | Anterios, Inc. | Use of nanoemulsions in the manufacture of a medicament for treating skin disorders |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| JP2013520424A (ja) * | 2010-02-19 | 2013-06-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
-
2013
- 2013-03-14 US US13/804,570 patent/US20130303519A1/en not_active Abandoned
- 2013-03-18 JO JOP/2013/0075A patent/JO3630B1/ar active
- 2013-03-19 NZ NZ700744A patent/NZ700744A/en not_active IP Right Cessation
- 2013-03-19 MA MA37438A patent/MA37438A1/fr unknown
- 2013-03-19 EA EA201491727A patent/EA036434B1/ru not_active IP Right Cessation
- 2013-03-19 GE GEAP201313599A patent/GEP20186900B/en unknown
- 2013-03-19 ES ES13714455T patent/ES2746946T3/es active Active
- 2013-03-19 MY MYPI2014702635A patent/MY175225A/en unknown
- 2013-03-19 SG SG11201405621UA patent/SG11201405621UA/en unknown
- 2013-03-19 UA UAA201411324A patent/UA117455C2/uk unknown
- 2013-03-19 CN CN201380015806.1A patent/CN104271129A/zh active Pending
- 2013-03-19 JP JP2015501852A patent/JP6373252B2/ja active Active
- 2013-03-19 EP EP13714455.6A patent/EP2827855B1/en active Active
- 2013-03-19 MX MX2014011324A patent/MX358411B/es active IP Right Grant
- 2013-03-19 SG SG10201607741RA patent/SG10201607741RA/en unknown
- 2013-03-19 AU AU2013235275A patent/AU2013235275B2/en active Active
- 2013-03-19 WO PCT/US2013/032962 patent/WO2013142491A1/en not_active Ceased
- 2013-03-19 CA CA2868024A patent/CA2868024A1/en not_active Abandoned
- 2013-03-19 KR KR1020147028776A patent/KR102128866B1/ko active Active
- 2013-03-19 IN IN8477DEN2014 patent/IN2014DN08477A/en unknown
- 2013-03-20 TW TW102109912A patent/TWI649082B/zh active
-
2014
- 2014-09-15 TN TNP2014000387A patent/TN2014000387A1/fr unknown
- 2014-09-16 IL IL234686A patent/IL234686B/en active IP Right Grant
- 2014-09-22 PH PH12014502109A patent/PH12014502109A1/en unknown
- 2014-10-17 ZA ZA2014/07551A patent/ZA201407551B/en unknown
-
2015
- 2015-09-03 US US14/844,270 patent/US10213436B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063525A1 (en) * | 2006-11-16 | 2008-05-29 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
Non-Patent Citations (6)
| Title |
|---|
| "A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 30 January 2012. URL:http://clinicaltrials.gov/archive/NCT01045421 /2012_01_30 * |
| "Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients" 6 December 2011 URL:http://clinicaltrials.gov/archive/NCT01091428/2011_12_06 * |
| KELLY KEVIN R ET AL: "Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)-An lnvestigational Aurora A Kinase Inhibitor-in Patients with Advanced Hematologic Malignancies", BLOOD; 53, vol. 118, n 21, 18 November 2011, p1061-1062. * |
| KOVAR HEINRICH: "AURKA Inhibitors: Right in Time", PEDIATRIC BLOOD & CANCER, vol. 55, no. 1, July 2010 (2010-07), pages 3-4. * |
| WANG TSO-FU ET AL: "A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck", JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 7, July 2008 (2008-07), pages 459-463. * |
| YAMAMOTO NOBUYUKI ET AL: "Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer", ANTICANCER RESEARCH, vol. 26, no. 1 B, January 2006 (2006-01 ), pages 777-781. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6263468B2 (ja) | Ｍｅｋ阻害剤およびオーロラａキナーゼの選択的阻害剤の組み合わせ | |
| JP6637884B2 (ja) | ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法 | |
| ES2622138T3 (es) | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa | |
| EP2376082A1 (en) | Combination of aurora kinase inhibitors and anti-cd20 antibodies | |
| TW202023563A (zh) | 新穎喹唑啉egfr抑制劑 | |
| US12459895B2 (en) | MEK inhibitors and uses thereof | |
| US10213436B2 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| WO2024173761A1 (en) | Combinations comprising mek inhibitors for use in the treatment of cancer | |
| AU2010322800A1 (en) | Small pyrimidine derivatives and methods of use thereof | |
| WO2023173057A1 (en) | Mek inhibitors and uses thereof | |
| WO2022187849A1 (en) | Salinomycin derivatives and uses thereof | |
| HK1206253B (en) | Combination of alisertib and paclitaxel for the treatment of cancer | |
| CN102105147B (zh) | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 | |
| HK1196296B (en) | Combination of mek inhibitors and selective inhibitors of aurora a kinase | |
| JP2015163591A (ja) | 抗癌剤の併用による癌治療方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |